Subject:
- Active Substance: Selinexor
- Name: Nexpovio®
- Therapeutic area: Multiple myeloma
- Pharmaceutical company: Stemline Therapeutics B.V.
Time table:
- Start: 01.10.2022
- Publication of assessment: 02.01.2023
- End of public hearing: 23.01.2023
- Final decision by G-BA: middle of March 2023
Comparative therapy:
- A patient-individual therapy taking into account prior therapies as well as degree and duration of response to treatment, choosing from:
- Bortezomib monotherapy
- Bortezomib + pegylated liposomal doxorubicin
- Bortezomib + dexamethasone
- Carfilzomib + lenalidomide + dexamethasone
- Carfilzomib + dexamethasone
- Daratumumab + lenalidomide + dexamethasone
- Daratumumab + bortezomib + dexamethasone
- Daratumumab monotherapy
- Elotuzumab + lenalidomide + dexamethasone
- Elotuzumab + pomalidomide + dexamethasone
- Isatuximab + pomalidomide + dexamethasone
- Ixazomib + lenalidomide + dexamethasone
- Lenalidomide + dexamethasone
- Panobinostat + bortezomib and dexamethasone
- Pomalidomide + bortezomib and dexamethasone
- Pomalidomide + dexamethasone
- Cyclophosphamide (in combination with additional antineoplastic drugs)
- Melphalan
- Doxorubicin
- Carmustine (in combination with other cytostatics and an adrenal cortex hormone, especially prednisone)
- Vincristine
- Dexamethasone
- Prednisolone
- Prednisone
- Best supportive care